Anesiva Announces Second Quarter 2008 Financial Results ... ( SOUTH SAN FRANCISCO Calif. Aug. 7...)

Anesiva Announces Second Quarter 2008 Financial Results and Update

Date:8/7/2008

SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported financial results and accomplishments for the second quarter and six months ended June 30, 2008.

"The 2008 second quarter marked a significant advance for Anesiva as we introduced Zingo(TM) in the U.S. pediatric hospital market," said Michael L. Kranda, president and chief executive officer. "In addition, I'm pleased to report that our Phase 3 trials of Adlea(TM) for the management of acute pain following total knee replacement surgeries and bunionectomy surgeries are nearing full patient enrollment. As a result, we anticipate releasing top-line data from both trials in the fourth quarter of this year."

"While we continue to make progress in our current commercial and clinical initiatives, I am conducting a full strategic review of the company's programs, timelines and resource allocations," Mr. Kranda said. "Based on the results of this evaluation, in early September I intend to present a comprehensive forward-looking plan for Anesiva's growth as a company focused on the late-stage development and commercialization of novel products that address unmet needs in the treatment of pain." Mr. Kranda was appointed Anesiva's president, chief executive officer and member of the board of directors in June 2008.

Second Quarter 2008 Financial Results

Total operating expenses in the second quarter of 2008 were $22.1 million, including $1.6 million in non-cash stock-based compensation, compared to total operating expenses of $14.7 million, including $2.4 million in non-cash stock- based compensation, in the second quarter of 2007. For the six months ended June 30, 2008, total operating expenses were $43.9 million compa
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook

Post Your Comments:

Anesiva Announces Second Quarter 2008 Financial Results ...( SOUTH SAN FRANCISCO Calif. Aug. 7...)